Page last updated: 2024-11-07

mono-n-demethyladinazolam

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

mono-N-demethyladinazolam: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID119094
CHEMBL ID436197
SCHEMBL ID7314825
MeSH IDM0143333

Synonyms (18)

Synonym
n-desmethyladinazolam
CHEMBL436197
u-42352
u 42352
8-chloro-n-methyl-6-phenyl-4h-(1,2,4)triazolo(4,3-a)(1,4)benzodiazepine-1-methanamine
4h-(1,2,4)triazolo(4,3-a)(1,4)benzodiazepine-1-methanamine, 8-chloro-n-methyl-6-phenyl-
37115-33-6
mono-n-desmethyladin azolam
n-desmethyladinozolam
nya2i3ddw4 ,
mono-n-demethyladinazolam
unii-nya2i3ddw4
ndmad
SCHEMBL7314825
8-chloro-1-[(methylamino)methyl]-6-phenyl-4h-s-triazolo[4,3-a][1,4]benzodiazepin
DTXSID00190612
n-[(8-chloro-6-phenyl-4h-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-1-yl)methyl]-n-methylamine
Q27285105

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Adinazolam half-life was prolonged approximately 40% in the elderly after oral dosing."( Pharmacokinetics and pharmacodynamics of adinazolam and N-desmethyladinazolam after oral and intravenous dosing in healthy young and elderly volunteers.
Ekernäs, SA; Fleishaker, JC; Grahnén, A; Hulst, LK, 1992
)
0.28
" Pharmacodynamic alterations were assessed using card sorting, digit-symbol substitution, and short-term memory tests."( Ranitidine does not alter adinazolam pharmacokinetics or pharmacodynamics.
Brouwer, KL; Dukes, GE; Fleishaker, JC; Hak, LJ; Koruda, M; Songer, SS; Suttle, AB, 1992
)
0.28
" Pharmacokinetic parameters were estimated by noncompartmental methods."( Comparison of adinazolam pharmacokinetics and effects in healthy and cirrhotic subjects.
Fleishaker, JC; Kroboth, PD; Maxwell, RA; Smith, RB; Van Thiel, DH, 1991
)
0.28
" NDMAD AUC (2541 +/- 457 versus 2798 +/- 447 ng h ml-1) and Cmax (173 +/- 30."( The lack of effect of smoking on the pharmacokinetics and pharmacodynamics of adinazolam and N-demethyladinazolam.
Chambers, JH; Fleishaker, JC, 1994
)
0.29
" NDMAD Asians had significantly higher NDMAD Cmax and AUC than Caucasians and African-Americans."( The pharmacokinetics and pharmacodynamics of adinazolam: multi-ethnic comparisons.
Ajir, K; Anderson, D; Chambers, JH; Fleishaker, JC; Lin, KM; Nuccio, I; Poland, RE; Smith, M; Zheng, Y, 1997
)
0.3

Dosage Studied

ExcerptRelevanceReference
" Adinazolam and NDMAD pharmacokinetics were linear throughout the dosage range studied."( Adinazolam pharmacokinetics and behavioral effects following administration of 20-60 mg oral doses of its mesylate salt in healthy volunteers.
Fleishaker, JC; Phillips, JP, 1989
)
0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID114395Tested for antagonism of oxotremorine hypothermia (OX) in mice1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
1-(Aminoalkyl)-6-aryl-4-H-s-triazolo[4,3-a][1,4]benzodiazepines with antianxiety and antidepressant activity.
AID114394Tested for antagonism of nicotine-induced tonic extensor convulsions (TE) in mice1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
1-(Aminoalkyl)-6-aryl-4-H-s-triazolo[4,3-a][1,4]benzodiazepines with antianxiety and antidepressant activity.
AID114562Tested for potentiation of yohimbine toxicity in aggregated mice(Y)1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
1-(Aminoalkyl)-6-aryl-4-H-s-triazolo[4,3-a][1,4]benzodiazepines with antianxiety and antidepressant activity.
AID114563Prolongation of hypoxic survival time (HS) in mice1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
1-(Aminoalkyl)-6-aryl-4-H-s-triazolo[4,3-a][1,4]benzodiazepines with antianxiety and antidepressant activity.
AID114393Tested for antagonism of nicotine-induced death (D) in mice1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
1-(Aminoalkyl)-6-aryl-4-H-s-triazolo[4,3-a][1,4]benzodiazepines with antianxiety and antidepressant activity.
AID114392Tested for antagonism of bicuculline-induced tonic-extensor convulsions (B) in mice1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
1-(Aminoalkyl)-6-aryl-4-H-s-triazolo[4,3-a][1,4]benzodiazepines with antianxiety and antidepressant activity.
AID114396Tested for antagonism of pentylenetetrazole-induced clonic convulsions (P) in mice1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
1-(Aminoalkyl)-6-aryl-4-H-s-triazolo[4,3-a][1,4]benzodiazepines with antianxiety and antidepressant activity.
AID114561Tested for potentiation of gamma-butyrolactone induced sleep (gamma-B) in mice1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
1-(Aminoalkyl)-6-aryl-4-H-s-triazolo[4,3-a][1,4]benzodiazepines with antianxiety and antidepressant activity.
AID114565Tested for stereotyped gnawing and licking behavior of mice pretreated with apomorphine (AG)1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
1-(Aminoalkyl)-6-aryl-4-H-s-triazolo[4,3-a][1,4]benzodiazepines with antianxiety and antidepressant activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (21.05)18.7374
1990's14 (73.68)18.2507
2000's1 (5.26)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.13

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.13 (24.57)
Research Supply Index3.50 (2.92)
Research Growth Index4.63 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.13)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials12 (60.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (40.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]